Crispr Theraptc (NASDAQ:CRSP) posted its earnings results on Wednesday. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02), Briefing.com reports. The firm had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.77) earnings per share.

Shares of Crispr Theraptc (CRSP) traded down $0.99 on Thursday, reaching $16.95. 348,021 shares of the company’s stock traded hands, compared to its average volume of 204,754. Crispr Theraptc has a twelve month low of $11.63 and a twelve month high of $25.00.

A number of analysts have recently weighed in on CRSP shares. Cann started coverage on shares of Crispr Theraptc in a report on Monday, July 17th. They set a “market perform” rating for the company. Barclays PLC restated a “buy” rating and issued a $29.00 price objective on shares of Crispr Theraptc in a report on Friday, September 8th. SunTrust Banks, Inc. started coverage on shares of Crispr Theraptc in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price objective for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Finally, Chardan Capital restated a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Crispr Theraptc has an average rating of “Buy” and an average price target of $23.08.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/09/crispr-theraptc-crsp-releases-earnings-results-misses-expectations-by-0-02-eps.html.

In related news, insider Samarth Kulkarni sold 27,154 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $20.08, for a total transaction of $545,252.32. Following the completion of the sale, the insider now owns 110,893 shares of the company’s stock, valued at $2,226,731.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kurt Von Emster sold 3,150 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $18.52, for a total transaction of $58,338.00. The disclosure for this sale can be found here. Insiders sold 343,060 shares of company stock valued at $6,778,681 over the last 90 days. 39.98% of the stock is currently owned by company insiders.

An institutional investor recently bought a new position in Crispr Theraptc stock. Vanguard Group Inc. bought a new position in Crispr Theraptc (NASDAQ:CRSP) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 17,019 shares of the company’s stock, valued at approximately $273,000. Hedge funds and other institutional investors own 25.52% of the company’s stock.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Receive News & Stock Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related stocks with our FREE daily email newsletter.